Press Release

FOR IMMEDIATE RELEASE CONTACT: Paul Roth

March 5, 2010 (213) 283-6570

ITCES Corporation Releases Preliminary Results of Year-Long

AVT-12 Weight Loss Controlled Trial

Los Angeles, CA, March 5 -- One-year Findings from Controlled Trial of AVT-12
Combination Drug Product on Weight Loss and Various Metabolic Risk Factors

A. Nielsen, P. Anderson, S. Das

Effective weight loss interventions ideally result not only in the promotion of
weight loss, but also contribute to favorable changes in metabolic risk
factors for chronic disease in overweight and obese subjects.

The weight loss combination drug product, AVT-12 is thought to improve

GPR39 affinity of the hormone, obestatin. Use of combination drug products
including agents targeted at distinct regulatory pathways may produce
significant additive or synergistic effects on weight loss.

The purpose of this study is to test the efficacy of AVT-12 in overweight and
obese individuals as compared to a placebo control group at 12 months. In
addition to bodyweight, measures include biochemical factors (total
cholesterol, high density lipoprotein, low density lipoprotein, triglycerides,
glucose, insulin, leptin and C-reactive protein.

At point of randomization, participants (n=451) were 47(11) (mean [SD])

years of age, with BMI 36.0(3.7) kg/m2, weight 98.1(10.4) kg.

One-year data are available for 94% of study participants (n=424) and
weight loss is -27.7(6.7), -3.2(2.8) kg for the treatment group and control
group, respectively, a weight loss of -39.3% and -3.4%, respectively.
CRP decreased significantly in the treatment group, from 9.3% in the lowest
risk category (CRP less than 1 ng/mL) at baseline, to 44.7% at 12 months,
but was essentially unchanged in the control group.

Findings from this study suggest that AVT-12 is an effective weight loss
combination drug product and may produce significant favorable changes in
risk factors for chronic disease.

The results of the latest AVT-12 trial are promising in that, not only did
participants lose substantial excess weight, but also demonstrated marked
improvements in risk-factor related blood profile parameters. In addition,
AVT-12 did not produce the problematic rise in blood pressure often elicited
by weight loss medications.

The sole side-effect noted was a mild, transient insomnia that persisted 24-
48 hours and self-resolved with continued use. This was mentioned by 1.4%
of participants and was not sufficient to require participant withdrawal. The
exemplary safety record of AVT-12 makes it potentially suitable for Over-
the-Counter (OTC) distribution.

About ITCES:

ITCES Corporation partners with innovators to evaluate and develop applied

biotherapeutics from concept to market. ITCES delivers timely value to clients by
facilitating and analyzing critical research, while protecting intellectual property.

###

Contact:
Paul Roth
Asst. Public Affairs Director
ITCES Corporation
(213) 283-6570
http://AVT12.info